Pharma Industry News

NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma

The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]